Table 1.

Characteristics of the clinical practice guidelines for the diagnosis and management of Duchenne muscular dystrophy.

Guideline developer	Year	Country	Included topics	Target users	Target patient or population	Guideline developers	Patient participation	Guideline review process	System used to grade recommendations
AAN (16)	2016	USA	Treatment	Not mentioned.	People with DMD.	American Association of Neurology	No	Clinical trials	CoE
Australian CPG (15)	2020	Australia	Assessment and management	Allied health, nursing professionals, medical professionals.	Individuals with DMD of any age from the point of diagnosis.	Allied health and nursing alliance Australia and New Zealand	No	Systematic reviews and expert consensus	Delphi GRADE COSMIN
Colombian CPG (18)	2015	Colombia	Diagnosis, treatment, and rehabilitation	General clinicians, pediatricians, neurologists, physiatrists, etc.	Patients with suspected or confirmed diagnosis of DMD.	COLCIENCIA	Yes	Systematic reviews, meta-analyses, clinical trials	GRADE
NICE (17)	2016	England	Treatment	Neurologists, neuromuscular specialists, rehabilitation specialists, neurogeneticists, pediatricians and primary care physicians.	People with DMD. Parents and caretakers of people with DMD.	Evaluation committee members and NICE project team	No	Clinical trials, double blinded	Not reported

NICE, National Institute for Clinical Excellence; DMD, Duchenne Muscular Dystrophy; AAN, American Academy of Neurology; USA, United States of America; CoE, Classes of Evidence; MINSA COL, Ministerio de Salud de Colombia; GRADE, Grading of Recommendations Assessment, Development and Evaluation.